WW Plunges 28.47% Amid Lilly Partnership

On May 2, 2025, WW experienced a significant drop of 28.47% in pre-market trading, marking a notable shift in its stock performance.

WW International Inc. has recently announced a strategic partnership with Eli Lilly, focusing on streamlining access to Lilly's weight-loss drug, Zepbound. This collaboration aims to enhance the availability of Zepbound single-dose vials for WeightWatchers Clinic members, particularly those with appropriate prescriptions. The surge in Zepbound prescriptions and the effectiveness of the app's tracking system in reducing drop-off rates have positioned WW for potential scalability with other therapies.

The partnership has been met with enthusiasm, as Zepbound usage among WeightWatchers Clinic members has more than doubled in recent months. This surge in demand highlights the growing acceptance and effectiveness of the drug within the WeightWatchers community. The streamlined access to Zepbound through LillyDirect® Pharmacy Provider is expected to further boost member satisfaction and retention.